UK launches FibCLOT®, LFB’s human fibrinogen concentrate
March 1, 2017

READ MORE >

2017 Rare Disease Day: LFB’s Commitment in the Field of Rare Diseases
February 28, 2017

READ MORE >

LFB S.A. announced today the acceptance by U.S. Food and Drug Administration of the filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)
January 6, 2017

READ MORE >

2015 – A strategic year for LFB
April 18, 2016

READ MORE >

LFB American Plasma LLC. partners with ImmunoTek BioCenters LLC, on long-term plasma supply agreement
March 18, 2016

READ MORE >

The LFB Group

A leader in the field of biopharmaceuticals in Europe

The LFB Group

Cultivating life-changing therapeutic proteins

The LFB Group

In the news